Haemonetics Stock Options

HAE Stock  USD 72.55  0.90  1.23%   
Haemonetics' latest option contracts expiring on October 17th 2025 are carrying combined implied volatility of 0.54 with a put-to-call open interest ratio of 2.08 over 37 outstanding agreements suggesting investors are buying way more puts than calls on contracts expiring on October 17th 2025.

Open Interest Against October 17th 2025 Option Contracts

The chart above shows Haemonetics' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Haemonetics' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Haemonetics' option, there is no secondary market available for investors to trade.

Haemonetics Maximum Pain Price Across 2025-10-17 Option Contracts

Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of particular securities such as Haemonetics close to expiration to expire worthless. So, Max pain occurs when market makers reach a net positive position across all options at a strike price where option holders stand to lose the most money. By contrast, Haemonetics' option sellers may reap the most after selling more options than buying, causing them to expire worthless.

In The Money vs. Out of Money Option Contracts on Haemonetics

Analyzing Haemonetics' in-the-money options over time can help investors to take a profitable long position in Haemonetics regardless of its overall volatility. This is especially true when Haemonetics' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Haemonetics' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Haemonetics' stock while costing only a fraction of its price.
Haemonetics' stock options are financial instruments that give investors the right to buy or sell shares of Haemonetics common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell Haemonetics stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If Haemonetics' stock price goes up or down, the stock options follow.
The current year's Liabilities And Stockholders Equity is expected to grow to about 2.6 B, whereas Common Stock Shares Outstanding is forecasted to decline to about 42.5 M.

Haemonetics In The Money Call Balance

When Haemonetics' strike price is surpassing the current stock price, the option contract against Haemonetics stock is said to be in the money. When it comes to buying Haemonetics' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Haemonetics are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.

Haemonetics Current Options Market Mood

Haemonetics' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Haemonetics Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.

Put-to-Call Open Interest

Put-to-Call Volume

Most options investors, including buyers and sellers of Haemonetics' calls and puts, are not very successful. It is estimated that an average options trader loses somewhere between 80% to 90% of the time. Haemonetics' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.

Rule 16 of the current Haemonetics contract

Base on the Rule 16, the options market is currently suggesting that Haemonetics will have an average daily up or down price movement of about 0.0338% per day over the life of the 2025-10-17 option contract. With Haemonetics trading at USD 72.55, that is roughly USD 0.0245. If you think that the market is fully incorporating Haemonetics' daily price movement you should consider buying Haemonetics options at the current volatility level of 0.54%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Purchasing Haemonetics options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Haemonetics calls. Remember, the seller must deliver Haemonetics stock to the call owner when a call is exercised.

Haemonetics Option Chain

When Haemonetics' strike price is surpassing the current stock price, the option contract against Haemonetics stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Haemonetics' option chain is a display of a range of information that helps investors for ways to trade options on Haemonetics. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Haemonetics. It also shows strike prices and maturity days for a Haemonetics against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone.
Open IntStrike PriceCurrent SpreadLast Price
Call
HAE251017C001350000135.00.0 - 2.152.15Out
Call
HAE251017C001300000130.00.0 - 2.152.15Out
Call
HAE251017C001250000125.00.0 - 2.152.15Out
Call
HAE251017C001200000120.00.0 - 2.152.15Out
Call
HAE251017C001150000115.00.0 - 2.152.15Out
Call
HAE251017C001100001110.00.0 - 1.81.8Out
Call
HAE251017C001050003105.00.0 - 2.22.2Out
Call
HAE251017C001000002100.00.0 - 2.32.3Out
Call
HAE251017C00095000395.00.0 - 2.42.4Out
Call
HAE251017C00090000090.00.0 - 2.652.65Out
Call
HAE251017C000850009385.00.0 - 3.22.27Out
Call
HAE251017C000800006980.00.85 - 4.43.3Out
Call
HAE251017C00075000575.02.15 - 6.35.6Out
Call
HAE251017C000700001170.05.0 - 8.97.0In
Call
HAE251017C000650001265.08.7 - 12.58.7In
Call
HAE251017C00060000160.012.8 - 16.612.8In
Call
HAE251017C00050000550.021.7 - 25.424.0In
 Put
HAE251017P001350000135.060.5 - 64.560.5In
 Put
HAE251017P001300000130.055.5 - 59.555.5In
 Put
HAE251017P001250000125.050.5 - 54.550.5In
 Put
HAE251017P001200000120.045.5 - 49.545.5In
 Put
HAE251017P001150000115.040.5 - 44.540.5In
 Put
HAE251017P001100000110.035.5 - 39.535.5In
 Put
HAE251017P001050000105.030.5 - 34.530.5In
 Put
HAE251017P001000000100.025.5 - 29.525.5In
 Put
HAE251017P00095000095.020.8 - 24.223.6In
 Put
HAE251017P00090000090.015.8 - 19.615.8In
 Put
HAE251017P00080000580.06.9 - 11.06.9In
 Put
HAE251017P0007500011675.03.9 - 7.85.4In
 Put
HAE251017P0007000017670.01.6 - 5.74.8Out
 Put
HAE251017P0006500010065.00.05 - 4.03.0Out
 Put
HAE251017P00060000160.00.55 - 3.22.65Out
 Put
HAE251017P00055000155.00.0 - 2.82.8Out
 Put
HAE251017P000500001150.00.0 - 2.152.15Out
 Put
HAE251017P00045000145.00.0 - 2.352.35Out
 Put
HAE251017P000400001440.00.0 - 2.252.25Out
 Put
HAE251017P00035000135.00.0 - 1.61.6Out

Haemonetics Selling And Marketing Expenses Over Time

   Selling And Marketing Expenses   
       Timeline  

Haemonetics Total Stockholder Equity

Total Stockholder Equity

546.72 Million

At present, Haemonetics' Total Stockholder Equity is projected to increase significantly based on the last few years of reporting.

Haemonetics Corporate Directors

Robert AbernathyIndependent DirectorProfile
Claire PomeroyIndependent DirectorProfile
Catherine BurzikIndependent DirectorProfile
Mark KrollIndependent DirectorProfile
When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.946
Earnings Share
3.31
Revenue Per Share
27.038
Quarterly Revenue Growth
(0.04)
Return On Assets
0.0665
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.